Overview

Azacitidine and Entinostat in Treating Patients With Newly Diagnosed Stage IA-IIIA Non-Small Lung Cancer Undergoing Surgery

Status:
Terminated

Trial end date:
2015-02-01

Target enrollment:

Participant gender:

Summary

This pilot clinical trials studies azacitidine and entinostat in treating patients with newly diagnosed stage IA-IIIIA non-small cell lung undergoing surgery. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Entinostat may stop the growth of cancer tumor cells by blocking some of the enzymes needed for cell growth. Giving azacitidine with entinostat may be an effective treatment for non-small cell lung cancer.

Phase:

Phase 1

Details

Lead Sponsor:

National Cancer Institute (NCI)

Treatments:

Azacitidine
Entinostat
Histone Deacetylase Inhibitors